Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3Phase 3 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Breast Neoplasms 145Lymphoma 104Lymphoma, Large B-Cell, Diffuse 76Sarcoma 62Hodgkin Disease 46Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Burkitt Lymphoma 35Triple Negative Breast Neoplasms 31Lymphoma, Non-Hodgkin 29Lymphoma, Mantle-Cell 27Leukemia 25Neoplasms 22Lymphoma, Follicular 22Neoplasm Metastasis 21Multiple Myeloma 21Neuroblastoma 20Carcinoma, Hepatocellular 18Ovarian Neoplasms 16Lymphoma, B-Cell 16Liver Neoplasms 14Urinary Bladder Neoplasms 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Osteosarcoma 12Lymphoma, T-Cell, Peripheral 11Lymphoma, Large-Cell, Anaplastic 11Inflammatory Breast Neoplasms 11Breast Neoplasms, Male 11Prostatic Neoplasms 10Dendritic Cell Sarcoma, Interdigitating 10Lymphoma, Large-Cell, Immunoblastic 9

Interventions

Etoposide 78Carboplatin 67Cisplatin 46durvalumab 26Topotecan 26atezolizumab 20Radiotherapy 19Irinotecan 19Paclitaxel 17anlotinib 16apatinib 15Nivolumab 15Drug Therapy 12pembrolizumab 9Platinum 9toripalimab 8tislelizumab 8Gemcitabine 8Bevacizumab 8Temozolomide 7Radiosurgery 7PM 01183 7Ipilimumab 7Pemetrexed 6Docetaxel 6Albumin-Bound Paclitaxel 6olaparib 5amrubicin 5Sunitinib 5surufatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Small Cell Lung Carcinoma × Doxorubicin × Clear all
NCT00483509 2019-10-04

NGR007

AGC Biologics S.p.A.

Phase 2 Completed
28 enrolled 10 charts
Thoracic

Small Cell Lung Carcinoma

NCT00759824 2015-02-12

A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide

European Lung Cancer Working Party

Phase 2 Completed
64 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT00003847 2013-09-05

VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer

Vertex Pharmaceuticals Incorporated

Phase 2 Terminated
36 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡